9 News & Press Releases found
Immunai News
-
Immunai Raises $215 Million to Accelerate Development of Its Immune-First Drug Actuary Platform
Immunai, a New York-based biotech company, today announced a $215M Series B, increasing the company’s total funding to date to $295M. The new capital will be used to expand Immunai’s “drug actuary” platform for target ...
-
Immunai Acquires Swiss Bioinformatics Firm Nebion
New York City- and Tel Aviv-based Immunai said the acquisition would allow it to expand its target discovery and drug development capabilities and that Nebion`s experience curating public gene expression datasets would help Immunai grow its ...
-
Data Driven: Immunai Adds Biocuration, European Hubs with Nebion Acquisition
Immunai has taken some important steps toward its quest to map the entire immune system by completing its second acquisition this year and bolstering its management and board with new executive and entrepreneurial expertise. Immunai has acquired ...
-
Immunai Recognized by Fast Company’s 2021 World Changing Ideas Awards
Immunai, a New York and Tel Aviv-based biotech company, today announced that it has been recognized as part of Fast Company’s World Changing Ideas Awards. The awards honor the businesses, policies, projects, and concepts that are actively ...
-
Immunai acquires single-cell data developer Dropprint Genomics to build out its immune system atlas
Shortly after raising $60 million to fuel its artificial intelligence work, aimed at digitally charting the human body’s immune system, Immunai announced it has acquired the single-cell sequencing software startup Dropprint Genomics. ...
-
Immunai Acquires Dropprint Genomics and Strengthens Leadership Team with Experts in Immunology to Expand Target Discovery Capabilities
Immunai, a New York and Tel Aviv-based biotech company, announced its acquisition of Dropprint Genomics, a San Francisco-based single-cell genomics software company. Immunai is also expanding its executive leadership team and scientific advisory ...
-
Immunai Using Acquisition, Funding to Shift Into Functional Work
With a recently closed $60 million funding round, the acquisition of software company Dropprint Genomics, and additions to its leadership team, immune profiling firm Immunai is looking to expand its functional genomics capabilities to more ...
-
Immunai Raises $60M to Reprogram Immunity
Immunai, a New York and Tel Aviv based biotech company, announced today $60M in funding, increasing the company’s total funding-to-date to over $80M. Immunai integrates multi-omic single-cell analytics and machine learning to identify novel ...
-
Immunai Launches to Fully Map the Entire Immune System to Better Develop Immunotherapies and Cell Therapies
Today, Immunai launches out of stealth to map the entire immune system for better detection, diagnosis, and treatment of disease. Leveraging single-cell technologies and machine learning algorithms, Immunai has mapped out millions of ...